Post COVID 19 multisystem inflammatory syndrome in an older adult

Parpas, Alexander; Yudd, Michael; Michaud, Jennine

doi:10.1080/0886022x.2021.1895839

Cited by 10 publications

(10 citation statements)

References 5 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 221 patients with MIS-A were identified: 102 were from the CDC’s MIS-C surveillance system, of whom 55 were described in a recent publication 3 ; 20 were from voluntary reports to the CDC, of whom 9 were included in a recent publication 2 ; and 99 were from case reports published in the literature. 2 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , …”

Section: Resultsmentioning

confidence: 99%

“…In total, 449 relevant articles were identified, and 86 were selected for in-depth review; of these, 60 had data for patients with MIS-A. 2 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 Figure 1 summarizes...…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults

et al. 2021

View full text Add to dashboard Cite

Key Points Question What are the clinical characteristics of multisystem inflammatory syndrome in adults (MIS-A)? Findings This systematic review of patients with MIS-A reported in the literature and to the US Centers for Disease Control and Prevention identified 221 patients worldwide. The syndrome presented approximately 4 weeks after acute COVID-19 with hyperinflammation and extrapulmonary multiorgan involvement that may be difficult to discern from acute biphasic COVID-19 and postacute sequelae of SARS-CoV-2 infection. Meaning These findings suggest that MIS-A occurs in the postacute COVID-19 period with a heterogeneous clinical presentation likely owing to a dysregulated immune response.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults

et al. 2021

View full text Add to dashboard Cite

show abstract

“…They increased liver volume as comorbidities independent of obesity, hypertension, diabetes mellitus, and heart disease status [ 74 ]. Similar to adults, multisystemic comorbidities were shown in the post-COVID-19 surveillance study in children and adolescents ( n = 186), which showed the gastrointestinal system in 92% patients, cardiovascular in 80%, respiratory in 70%, with hematologic (76%), and mucocutaneous (74%) changes [ 75 , 76 ].…”

Section: Impact On Immune System Multi-organ Damage and Other Symptomsmentioning

confidence: 96%

Evidence mapping and review of long-COVID and its underlying pathophysiological mechanism

Umesh

Pranay

Pandey³

et al. 2022

Infection

View full text Add to dashboard Cite

Purpose Apart from the global disease burden of acute COVID-19 disease, the health complications arising after recovery have been recognized as a long-COVID or post-COVID-19 syndrome. Evidences of long-COVID symptoms involving various organ systems are rapidly growing in literature. The objective was to perform a rapid review and evidence mapping of systemic complications and symptoms of long-COVID and underlying pathophysiological mechanisms. Methods Publications reporting clinical trials, observational cohort studies, case–control studies, case-series, meta-analysis, and systematic reviews, focusing on the squeal of the disease, consequences of COVID-19 treatment/hospitalization, long-COVID, chronic COVID syndrome, and post acute COVID-19 were reviewed in detail for the narrative synthesis of frequency, duration, risk factors, and pathophysiology. Results The review highlights that pulmonary, neuro-psychological, and cardiovascular complications are major findings in most epidemiological studies. However, dysfunctional gastrointestinal, endocrine, and metabolic health are recent findings for which underlying pathophysiological mechanisms are poorly understood. Analysis of the clinical trial landscape suggests that more than 50% of the industry-sponsored trials are focused on pulmonary symptoms. In contrast to the epidemiological trends and academic trials, cardiovascular complications are not a focus of industry-sponsored trials, suggestive of the gaps in the research efforts. Conclusion The gap in epidemiological trends and academic trials, particularly concerning cardiovascular complications not being a focus of industry-sponsored trials is suggestive of the gaps in research efforts and longer follow-up durations would help identify other long-COVID-related health issues such as reproductive health and fertility. Supplementary Information The online version contains supplementary material available at 10.1007/s15010-022-01835-6.

show abstract

“…Although the exact mechanism of MIS-A is unknown, it appears by reason of a delay in the cytokine storm associated with the initial infection ( Parpas et al, 2021 ). Viral infections are caused by a mechanism considered antibody-dependent enhancement (ADE), which increases the level of neutralizing antibodies and may lead to pathogenicity, while SARS-CoV-2 antibodies are supposed to be have protective and neutralizing properties.…”

Section: Introductionmentioning

confidence: 99%

Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities

Hosseini

Fallahi

Erabi

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), has led to huge concern worldwide. Some SARS-CoV-2 infected patients may experience post–COVID-19 complications such as multisystem inflammatory syndrome, defined by symptoms including fever and elevated inflammatory markers (such as elevation of C reactive protein (CRP), erythrocyte sedimentation rate, fibrinogen, procalcitonin test, D-dimer, ferritin, lactate dehydrogenase or IL-6, presence of neutrophilia, lymphopenia, decreased albumin, and multiple organ dysfunction). Post–COVID-19 complications may also manifest as autoimmune diseases such as Guillain-Barré syndrome and systemic lupus erythematosus. Signaling disorders, increased inflammatory cytokines secretion, corticosteroid use to treat COVID-19 patients, or impaired immune responses are suggested causes of autoimmune diseases in these patients. In this review, we discuss the molecular and pathophysiological mechanisms and therapeutic opportunities for multisystem inflammatory syndrome and autoimmune diseases following SARS-CoV-2 infection with the aim to provide a clear view for health care providers and researchers.

show abstract

Post COVID 19 multisystem inflammatory syndrome in an older adult

Cited by 10 publications

References 5 publications

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults

Evidence mapping and review of long-COVID and its underlying pathophysiological mechanism

Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities

Contact Info

Product

Resources

About